Addex Therapeutics to Participate at the H.C. Wainwright 22nd Annual Global Investment Conference
September 14 2020 - 1:00AM
Geneva, Switzerland, September 14,
2020 - Addex Therapeutics Ltd (SIX
and Nasdaq: ADXN), a leading company pioneering allosteric
modulation-based drug discovery and development today announced
that Tim Dyer, Chief Executive Officer, is scheduled to
participate at the Virtual H.C. Wainwright 22nd Annual Global
Investment Conference taking place on September 14 – September 16,
2020.
Mr. Dyer will participate and present Addex on
September 15, 2020 at 16:30 EDT / 22:30 CEST. You can follow the
event by following this link.
Mr. Dyer will be available for one-on-one
meetings during the conference. Meetings can be requested via the
HCW Login page for those who registered to participate.
About Addex Therapeutics
Addex Therapeutics is a clinical-stage
pharmaceutical company focused on the development and
commercialization of an emerging class of novel orally available
small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional non-allosteric molecules and
may offer an improved therapeutic approach to conventional
"orthosteric" small molecule or biological drugs. Addex's
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex's lead drug candidate, dipraglurant (mGlu5
negative allosteric modulator or NAM), is scheduled to enter a
pivotal registration clinical trial for Parkinson’s disease
levodopa induced dyskinesia (PD-LID). In parallel, dipraglurant's
therapeutic use in dystonia is being investigated in preclinical
models. Addex's second clinical program, ADX71149 (mGlu2 positive
allosteric modulator or PAM), is being developed in collaboration
with Janssen Pharmaceuticals, Inc for the treatment of epilepsy. In
addition, Addex’s GABAB PAM program has been licensed to
Indivior PLC for the treatment of addiction. Preclinical programs
include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for
mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease
and mGlu3 PAM for neurodegenerative
disorders.
Press Contacts:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55Email:
PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
Disclaimer / Forward-looking
statements: This communication does not constitute an
offer or invitation to subscribe for or purchase any securities of
Addex Therapeutics Ltd. This publication may contain certain
forward-looking statements concerning the Company and its business.
Such statements involve certain risks, uncertainties and other
factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially
different from those expressed or implied by such statements.
Readers should therefore not place undue reliance on these
statements, particularly not in connection with any contract or
investment decision. The Company disclaims any obligation to update
these forward-looking statements.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Apr 2023 to Apr 2024